Bioequivalence Study of Rosuvastatin Tablet

• Status: Recruiting
• Trial end date: 2022-12-15
• Target enrollment: 0
• Participant gender: Male

Summary

This study is designed to explore the bioequivalence of Test Product Vaptor (Rosuvastatin) 20 mg Tablet with the reference product Crestor (Rosuvastatin) 20 mg tablet under fasting conditions in healthy Pakistani male subjects.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Karachi
• Collaborator: The Searle Company Limited
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Healthy male volunteers aged 18 to 55 years inclusive.

• Subjects with a body mass index from 18.5 to 30 kg/m2 (both inclusive).

• Subjects who are healthy as determined by routine physical examination, including vital sign monitoring (ie, blood pressure, heart rate, and temperature), 12 Lead ECG, and laboratory analysis (ie, hematology, blood biochemistry, and urinalysis)and viral serology as determined by the investigator.

• Subjects should have negative urine test for drugs of abuse (MOP and THC will be tested) and alcohol breath analysis at screening and prior to each check-in.

• Subjects will be able to, understand and sign the Informed Consent Form for Medical Screening during their screening visit and Participation Informed Consent Form on study check-In day.

Exclusion Criteria:

• History of smoking (≥3 cigarette/day), alcoholism, and test for drug of abuse, heavy pan or gutka user as judged by teeth / mouth inspection.

• Subjects with clinically relevant evidence of cardiovascular, gastrointestinal/hepatic, renal, psychiatric, respiratory, urogenital, hematologic/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, drug hypersensitivity, allergy, endocrine, major surgery or other relevant diseases as revealed by medical history, physical examination, and laboratory assessments which may interfere with the absorption, distribution, metabolism or elimination of drugs or constitute a risk factor when taking study medication.

• Subject is allergic to Rosuvastatin and/or other HMG-COA inhibitors.

• Subject has received any investigational drug within 30 days.

• Subjects with salt imbalance in the blood (especially low levels of potassium or magnesium in the blood).

• Donation or loss of more than 450 mL of blood within 3 months prior to the screening.

• Ingestion of OTC drug, within 7 days of drug administration.

• History of intake of any prescribed medicine during a period of 30 days, prior to drug administration day of study.

• History of any significant illness in the last four weeks.

• Subjects with history of renal impairement, liver disease, hypothyrodism, myopathy and rhabdomyolysis.

• Subject taking any vitamins or herbal supplements during within last 14 days of drug administration.

• Subjects who smoke and/or take nicotine in any form. Non-smoking subjects, who have previously smoked, should at least be non-smoking for 6 months prior to dosing.

• Concomitant treatment with cyclosporine, gemfibrozil, Protease Inhibitors (atazanavir and ritonavir, lopinavir and ritonavir or simeprevir), Coumarin Anticoagulant (warfarin), Niacin, Fenofibrate, Colchicine, ezetimibe, erythromycin,an oral contraceptive/ hormone replacement therapy( ethinyl estradiol and norgestrel), fusidic acid.

• Consumption of grapefruit and/or its products within 14 days prior to the start of study.

• Subjects who test positive for syphilis (VDRL) or who are known to have serum hepatitis or who are carriers of the Hepatitis B surface antigen (HBsAg) or are carriers of antibodies to hepatitis C virus (anti-HCV) or to the human immunodeficiency virus (HIV-1 or HIV-2).

• Individuals having undergone any major surgery within 3 months prior to the start of the study, unless deemed eligible, otherwise by the Principal Investigator or whomever he may designate.

• Inability to take oral medication.

• Subjects with any condition, which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or elimination of drugs.

• Subjects with clinically significant abnormalities in investigations (safety assessments) as determined by the Investigator.